Associate Professor Anna Hearps
Co-Program Director, Disease Elimination; Head, Infection, Inflammation and Innate Immunity
Working groups
Burnet publications
View 65 moreCharacterisation of vaginal Lactobacillus isolates from South African women towards the development of a biotherapeutic to optimise the vaginal microbiome
bioRxiv (Cold Spring Harbor Laboratory)
Jenna M. Wilson et al
Utility of longitudinal assessment of plasma biomarkers to predict cardiovascular disease in people with HIV
HIV Research & Clinical Practice
Janine M. Trevillyan et al
Lactic acid produced by optimal vaginal Lactobacillus spp. potently and specifically inactivates HIV-1 in vitro by targeting the viral RNA genome and reverse transcriptase
PLoS Pathogens
Muriel Aldunate et al
Reports and other work
-
Covid-19 Global Trends and Analysis - Volume 2: SARS-CoV-2 viral load dynamics and infectivity.
Covid-19 Global Trends and Analysis - Volume 2: SARS-CoV-2 viral load dynamics and infectivity.
Current projects
View 10 moreImmunotherapy-based approaches to cure HIV
The objectives of this project include identifying the relevant NK subset which is the most potent killer of HIV-infected cells and developing anti-HIV antibodies with enhanced function.
Getting to the heart of cardiovascular disease in viral infections
This project aims to understand the mechanisms of how viral infections can potentiate the development of CVD, with a particular focus on the role monocytes may play in this process.
Methamphetamine and injecting drug use cohort studies: MIXMAX
MIXMAX is the largest active cohort study of people who use drugs in Australia. It combines 2 pre-existing studies: SuperMIX and VMAX.
